Risperidone and Stroke Risk in Dementia: Recent Research Raises Concerns

A large-scale UK study has revealed a concerning link between the use of risperidone, a common antipsychotic medication, and an increased risk of stroke in individuals with dementia. The findings, published in the British Journal of Psychiatry and reported by ScienceDaily, challenge previous assumptions about patient safety and highlight the need for cautious prescribing practices.

What is Risperidone and Why is it Used in Dementia Care?

Risperidone is a powerful antipsychotic medication often prescribed to dementia patients experiencing severe agitation or aggressive behavior. It’s frequently used in care homes when non-pharmacological approaches have proven ineffective in managing distressing symptoms. Currently, risperidone is the only drug of its kind licensed for use in dementia patients in the UK.

Key Findings of the Study

Researchers analyzed anonymized health records from nearly 165,000 dementia patients in the UK between 2004 and 2023. The study, detailed in PubMed, found that risperidone use was associated with a 28% increased risk of stroke compared to those not taking the medication (adjusted hazard ratio: 1.28; 95% CI: 1.20-1.37).

Importantly, the increased stroke risk was observed across all patient subgroups, including those with no prior history of heart disease or stroke. This finding contradicts earlier beliefs that certain patients might be less vulnerable to the drug’s side effects. The incidence rate of stroke was substantially higher in those with a prior history of stroke (222 per 1000 person-years) and cardiovascular disease (94.1 per 1000 person-years) although taking risperidone, but the medication still increased risk even in patients without these pre-existing conditions (2.9% vs 2.2%).

No “Safe” Group Identified

“We knew Risperidone causes stroke, but we didn’t realize whether some groups of people might be more at risk than others,” explained Dr. Byron Creese of Brunel University of London, as reported by ScienceDaily. “We thought if we might identify characteristics that make people more at risk, doctors could avoid prescribing to patients with those characteristics.” The study found no such identifiable “safe” group.

Balancing Risks and Benefits

Approximately half of all individuals living with dementia experience agitation, which can be deeply distressing for both patients and their caregivers. While non-pharmacological interventions are the first line of treatment, risperidone may be considered as a last resort when behavioral therapies fail. This presents a difficult dilemma for doctors and families, who must weigh the drug’s potential to calm severe agitation against the risk of serious side effects like stroke.

Current Guidance and Monitoring Concerns

Current National Health Service (NHS) guidance recommends limiting risperidone treatment to six weeks for severe symptoms. However, many patients continue the medication for longer periods, and monitoring practices vary across the country. There are currently no licensed alternative drugs in the UK specifically for treating severe agitation in dementia patients, further complicating the situation.

What This Means for Patients and Doctors

These findings emphasize the importance of open and honest conversations between doctors, patients, and families regarding the risks and benefits of risperidone. Dr. Creese stated, “These findings give clearer information about who is most at risk, which helps everyone make more informed choices. Every decision should be based on what is right for each person, through honest conversations between doctors, patients, and families.” Researchers hope the data will inform updated, more person-centered clinical guidance.

Key Takeaways

• Risperidone is linked to an increased risk of stroke in dementia patients, even those without prior cardiovascular issues.
• No specific group of dementia patients is demonstrably “safe” from this risk.
• Careful consideration of risks and benefits is crucial when prescribing risperidone.
• Improved monitoring and updated clinical guidance are needed.